---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-025946"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T17:59:39.059108+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CorMedix: Q1 net loss $7.0M; FDA accepts DefenCath NDA resubmission with 6-mo review

## Summary
- Net loss $7.0M ($0.18/shr) vs $7.2M ($0.20/shr) in Q1 2021; operating expenses down 3%.
- FDA accepted DefenCath NDA resubmission as complete Class 2 response with 6-month review; inspection planned.
- New CEO Joe Todisco officially started May 10; CCO Tom Nusbickel departed by mutual agreement.
- Donna Ucci (SVP Global Quality) and Frank Raffaele (VP Supply Chain) hired; Liz Hurlburt promoted.
- Winding down European ops, discontinuing Neutrolin distribution to focus on US DefenCath launch.

## SEC filing metadata
- accession: 0001213900-22-025946
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390022025946/0001213900-22-025946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390022025946/ea159840-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-025946
- JSON: https://secwatch.observer/filing/0001213900-22-025946.json
- Plain text: https://secwatch.observer/filing/0001213900-22-025946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.